Shares of Epizyme EPZM were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 9.43% over the past year to ($0.58), which beat the estimate of ($0.61).
Revenue of $2,467,000 decreased by 58.19% from the same period last year, which missed the estimate of $4,300,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Price Action
Company's 52-week high was at $27.82
Company's 52-week low was at $9.73
Price action over last quarter: down 21.35%
Company Description
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.